trending Market Intelligence /marketintelligence/en/news-insights/trending/Y1g_f8o_fCSX2XA5IFUlkw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Cytori broadens product pipeline with 2 oncology drugs

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Cytori broadens product pipeline with 2 oncology drugs

Cytori Therapeutics Inc. is acquiring certain assets from privately held Azaya Therapeutics to boost its position in regenerative medicine.

The company will have access to Azaya's proprietary nanoparticle development platform after issuing $2 million worth of its stock and extinguishing $2 million of the company's trade payables.

The acquisition expands Cytori's product portfolio with two cancer drugs: ATI-0918 and ATI-1123.

Azaya is eligible for up to an additional $16.3 million in commercial milestone-related payments and up to $100 million in royalties on product sales.

Cytori may also pay Azaya up to $50 million if it licenses the drug candidates to a third party as a result of the agreement, which is expected to close by Feb. 28.

Cytori also plans to lease Azaya's protein-stabilized nanoparticle manufacturing and development facility for five years as it advances the drug candidates.